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In my short communication “Endogenous retroviruses expressed in
uman tumours cannot be used as targets for anti-tumour vaccines ” [1] ,
 indicated possible risk factors when human endogenous retroviruses
HERVs), which are highly expressed in some human tumours and in
he placenta, will be used as targets for tumour vaccination and im-
unotherapy. The main risk factors are expression of HERVs on human
mbryonic stem cells (ESC), and on immune and other cells. Expres-
ion on human ESC is well-documented [2] , expression on immune and
ther cells is documented at least after infections (for review see [3] ).
nteraction of the vaccine or therapy with these normal cells may be
armful. 
In the accompanying comment, Holst and co-workers deny these risk
actors [4] , partially not recognising the virological background. For ex-
mple, in one of their studies in a mouse model [5] , they immunised
gainst the melanoma associated retrovirus (MelARV) using an aden-
viral vector and prevented colorectal tumor growth and progression in
ice. However, MelARV is not an endogenous retrovirus, it is a recom-
inant virus not present in the murine genome. It is also not surprising
hat immunisation against proteins of HERV-K, artificially expressed on
he surface of mouse tumour cells, successfully reduced tumour growth
n the mouse [6] . The HERV- proteins are not expressed on mouse ESC
nd mouse immune cells. 
In the human system, the authors claim that “existing HERV-K-
pecific T cell responses induced in human breast and ovarian cancers
oints towards a favorable safety profile ” [4] . However, in these studies
ytotoxic T cells killing HERV-K-expressing tumour cells were induced
nly in vitro , but not in vivo , in the patient [7 , 8] . These HERV-K-specific
ytotoxic cells did not kill normal cells, but there were no investigations
hether human ESC were among these normal cells. 
Further, the authors compare HERV antigens with fetal antigens.
hey argue, that clinical vaccine trials in phase 3 for the fetal
ntigen melanoma-associated antigen A3 (MAGE-A3) and a specific
AR(chimeric antigen receptor)-T cell therapy targeting the New York
sophageal squamous cell cancer-1 (NY-ESO-1) were performed with-
ut specific safety signals. The truth is, that the study using MAGE-A3
ad been stopped [9] . Whereas the cancer testis antigen MAGE-A3 is
ndeed expressed on human ESCs [10] , I was unable to find such data
or NY-ESO-1. 
The authors claim that I ignore the fact that immune responses
gainst antigens expressed on dendritic cells are a natural part of tu-
or immune responses, but I don´t do this and this has nothing to doDOI of original article: 10.1016/j.tranon.2021.101040 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) ith a potential harmful effect of vaccination against HERVs as tumour
reatment. 
In conclusion, there is no evidence for an effective and safe applica-
ion of HERVs as targets for tumour vaccination and I repeat my sen-
ence, that “anti-retroviral vaccines should not be used without further
afety investigations in this field ” [1] . 
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